Qinlock (ripretinib) — CareFirst (Caremark)
Gastrointestinal stromal tumor (GIST)
Initial criteria
- Diagnosis of advanced, gross residual (R2 resection), unresectable, tumor rupture, recurrent, or metastatic GIST
- Used as a single agent
- Member has previously received treatment with 3 or more kinase inhibitors, including imatinib OR member has experienced disease progression on avapritinib and dasatinib OR member is intolerant to sunitinib as second-line therapy after imatinib
Reauthorization criteria
- No evidence of unacceptable toxicity while on the current regimen
Approval duration
12 months